A prospective, cohort, multicentre study of candidaemia in hospitalized adult patients with haematological malignancies

Clinical Microbiology and Infection

Volumn 20, Issue 1, 2014, Pages

  Gamaletsou, M N ^a,b   Walsh, T J ^b   Zaoutis, T ^c   Pagoni, M ^d   Kotsopoulou, M ^e   Voulgarelis, M ^a   Panayiotidis, P ^a   Vassilakopoulos, T ^a   Angelopoulou, M K ^a   Marangos, M ^f   Spyridonidis, A ^f   Kofteridis, D ^g   Pouli, A ^h   Sotiropoulos, D ⁱ   Matsouka, P ^j   Argyropoulou, A ^d   Perloretzou, S ^e   Leckerman, K ^c   Manaka, A ^d   Oikonomopoulos, P ^d   Daikos, G ^a   Petrikkos, G ^a   Sipsas, N V ^a   more..

^a UNIVERSITY OF ATHENS   (Greece)

^b WEILL CORNELL MEDICAL CENTER   (United States)

^c CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^d EVANGELISMOS HOSPITAL   (Greece)

^e METAXA CANCER HOSPITAL   (Greece)

^f UNIVERSITY OF PATRAS   (Greece)

^g UNIVERSITY OF CRETE   (Greece)

^h Ayios Savvas Hospital   (Greece)

ⁱ Papanikolaou Hospital   (Greece)

^j UNIVERSITY OF THESSALY   (Greece)

more..

Author keywords

Candidaemia; Haematological malignancy; Incidence; Outcome; Risk factors

Indexed keywords

ANTIFUNGAL AGENT;

ADULT; ARTICLE; CANDIDA ALBICANS; CANDIDA PARAPSILOSIS; CANDIDEMIA; CENTRAL VENOUS CATHETER; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HEMATOLOGIC MALIGNANCY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HOSPITAL ADMISSION; HUMAN; IMMUNOGLOBULIN DEFICIENCY; INCIDENCE; MALE; MORTALITY; MULTICENTER STUDY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RISK FACTOR;

CANDIDA; CANDIDA ALBICANS; CANDIDA PARAPSILOSIS;

CANDIDAEMIA; HAEMATOLOGICAL MALIGNANCY; INCIDENCE; OUTCOME; RISK FACTORS;

ADOLESCENT; ADULT; AGAMMAGLOBULINEMIA; AGED; AGED, 80 AND OVER; ANTIFUNGAL AGENTS; CANDIDA; CANDIDEMIA; CASE-CONTROL STUDIES; CENTRAL VENOUS CATHETERS; FEMALE; GREECE; HEMATOLOGIC NEOPLASMS; HOSPITALIZATION; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RISK FACTORS; YOUNG ADULT;

EID: 84890792170     PISSN: 1198743X     EISSN: 14690691     Source Type: Journal    
DOI: 10.1111/1469-0691.12312     Document Type: Article

References (35)

1. Zaoutis TE, Argon J, Chu J, Berlin JA, Walsh TJ, Feudtner C. The epidemiology and attributable outcomes of candidemia in adults and children hospitalized in the United States: a propensity analysis. Clin Infect Dis 2005; 41: 1232-1239.
2. Fortún J, Martín-Dávila P, Gómez-García de la Pedrosa E et al. Emerging trends in candidemia: a higher incidence but a similar outcome. J Infect 2012;65:64-70.
3. Sipsas NV, Lewis RE, Tarrand J et al. Candidemia in patients with hematologic malignancies in the era of new antifungal agents (2001-2007): stable incidence but changing epidemiology of a still frequently lethal infection. Cancer 2009; 115: 4745-4752.
4. Zirkel J, Klinker H, Kuhn A et al. Epidemiology of Candida blood stream infections in patients with hematological malignancies or solid tumors. Med Mycol 2012; 50: 50-55.
5. Viscoli C, Girmenia C, Marinus A et al. Candidemia in cancer patients: a prospective, multicenter surveillance study by the Invasive Fungal Infection Group (IFIG) of the European Organization for Research and Treatment of Cancer (EORTC). Clin Infect Dis 1999; 28: 1071-1079.
6. Kontoyiannis DP, Marr KA, Park BJ et al. Prospective surveillance for invasive fungal infections in hematopoietic stem cell transplant recipients, 2001-2006: overview of the Transplant-Associated Infection Surveillance Network (TRANSNET) Database. Clin Infect Dis 2010; 50: 1091-1100.
7. Horn DL, Neofytos D, Anaissie EJ et al. Epidemiology and outcomes of candidemia in 2019 patients: data from the prospective antifungal therapy alliance registry. Clin Infect Dis 2009; 48: 1695-1703.
8. Slavin MA, Sorrell TC, Marriott D et al. Candidaemia in adult cancer patients: risks for fluconazole-resistant isolates and death. J Antimicrob Chemother 2010; 65: 1042-1051.
9. De Pauw B, Walsh TJ, Donnelly JP et al. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis 2008; 46: 1813-1821.
10. Antoniadou A, Torres HA, Lewis RE et al. Candidemia in a tertiary care cancer center: in vitro susceptibility and its association with outcome of initial antifungal therapy. Medicine (Baltimore) 2003; 82: 309-321.
11. Clinical and Laboratory Standards Institute. Reference method for broth dilution antifungal susceptibility testing of yeasts; fourth informational supplement. CLSI document M27-S4. Clinical and Laboratory Standards Institute, Wayne, PA (in press).
12. Bassetti M, Trecarichi EM, Righi E et al. Incidence, risk factors, and predictors of outcome of candidemia. Survey in 2 Italian university hospitals. Diagn Microbiol Infect Dis 2007; 58: 325-331.
13. Bow EJ, Laverdière M, Lussier N, Rotstein C, Cheang MS, Ioannou S. Antifungal prophylaxis for severely neutropenic chemotherapy recipients: a meta analysis of randomized-controlled clinical trials. Cancer 2002; 94: 3230-3246.
14. Blanchard E, Lortholary O, Boukris-Sitbon K, Desnos-Ollivier M, Dromer F, Guillemot D; French Mycosis Study Group. Prior caspofungin exposure in patients with hematological malignancies is a risk factor for subsequent fungemia due to decreased susceptibility in Candida spp.: a case-control study in Paris, France. Antimicrob Agents Chemother 2011; 55: 5358-5361.
15. Luo G, Ibrahim AS, French SW, Edwards JE Jr, Fu Y. Active and passive immunization with rHyr1p-N protects mice against hematogenously disseminated candidiasis. PLoS One 2011; 6: e25909.
16. Xin H, Cartmell J, Bailey JJ, Dziadek S, Bundle DR, Cutler JE. Self-adjuvanting glycopeptide conjugate vaccine against disseminated candidiasis. PLoS One 2012; 7: e35106.
17. Spellberg B, Ibrahim AS, Lin L et al. Antibody titer threshold predicts anti-candidal vaccine efficacy even though the mechanism of protection is induction of cell-mediated immunity. J Infect Dis 2008; 197: 967-971.
18. Andes DR, Safdar N, Baddley JW et al. Impact of treatment strategy on outcomes in patients with candidemia and other forms of invasive candidiasis: a patient-level quantitative review of randomized trials. Clin Infect Dis 2012; 54: 1110-1122.
19. Kollef M, Micek S, Hampton N, Doherty JA, Kumar A. Septic shock attributed to Candida infection: importance of empiric therapy and source control. Clin Infect Dis 2012; 54: 1739-1746.
20. Sipsas NV, Kontoyiannis DP. Invasive fungal infections in patients with cancer in the Intensive Care Unit. Int J Antimicrob Agents 2012; 39: 464-471.
21. Guzman JA, Tchokonte R, Sobel JD. Septic shock due to candidemia: outcomes and predictors of shock development. J Clin Med Res 2011; 3: 65-71.
22. Brion LP, Uko SE, Goldman DL. Risk of resistance associated with fluconazole prophylaxis: systematic review. J Infect 2007; 54: 521-529.
23. Nihtinen A, Anttila VJ, Elonen E, Juvonen E, Volin L, Ruutu T. Effect of fluconazole prophylaxis on the incidence of invasive Candida infections and bacteraemias in patients with acute leukaemia. Eur J Haematol 2008; 80: 391-396.
24. Lin MY, Carmeli Y, Zumsteg J et al. Prior antimicrobial therapy and risk for hospital-acquired Candida glabrata and Candida krusei fungemia: a case-case-control study. Antimicrob Agents Chemother 2005; 49: 4555-4560.
25. Walsh TJ. Echinocandins: an advance in the primary treatment of invasive candidiasis. N Engl J Med 2002; 347: 2070-2072.
26. Kahn JN, Garcia-Effron G, Hsu MJ, Park S, Marr KA, Perlin DS. Acquired echinocandin resistance in a Candida krusei isolate due to modification of glucan synthase. Antimicrob Agents Chemother 2007; 51: 1876-1878.
27. Pfeiffer CD, Garcia-Effron G, Zaas AK, Perfect JR, Perlin DS, Alexander BD. Breakthrough invasive candidiasis in patients on micafungin. J Clin Microbiol 2010; 48: 2373-2380.
28. Lortholary O, Desnos-Ollivier M, Sitbon K, Fontanet A, Bretagne S, Dromer F; French Mycosis Study Group. Recent exposure to caspofungin or fluconazole influences the epidemiology of candidemia: a prospective multicenter study involving 2, 441 patients. Antimicrob Agents Chemother 2011; 55: 532-538.
29. Pappas PG, Kauffman CA, Andes D et al. Infectious Diseases Society of America. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis 2009; 48: 503-535.
30. Nucci M, Anaissie E, Betts RF et al. Early removal of central venous catheter in patients with candidemia does not improve outcome: analysis of 842 patients from 2 randomized clinical trials. Clin Infect Dis 2010; 51: 295-303.
31. Silva S, Henriques M, Martins A, Oliveira R, Williams D, Azeredo J. Biofilms of non-Candida albicans Candida species: quantification, structure and matrix composition. Med Mycol 2009; 47: 681-689.
32. Bonassoli LA, Bertoli M, Svidzinski TI. High frequency of Candida parapsilosis on the hands of healthy hosts. J Hosp Infect 2005; 59: 159-162.
33. Tortorano AM, Peman J, Bernhardt H et al. Epidemiology of candidaemia in Europe: results of 28-month European Confederation of Medical Mycology (ECMM) hospital-based surveillance study. Eur J Clin Microbiol Infect Dis 2004; 23: 317-322.
34. Berenguer J, Buck M, Witebsky F, Stock F, Pizzo PA, Walsh TJ. Lysis-centrifugation blood cultures in the detection of tissue-proven invasive candidiasis. Disseminated versus single-organ infection. Diagn Microbiol Infect Dis 1993; 17: 103-109.
35. Chamilos G, Luna M, Lewis RE et al. Invasive fungal infections in patients with hematologic malignancies in a tertiary care cancer center: an autopsy study over a 15-year period (1989-2003). Haematologica 2006; 91: 986-989.